Last reviewed · How we verify
IV iron dextran
At a glance
| Generic name | IV iron dextran |
|---|---|
| Also known as | INFeD®, Cosmofer® |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of PVT401 in Healthy Subjects (PHASE1)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) (PHASE1)
- Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient (PHASE3)
- Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (PHASE2)
- Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV iron dextran CI brief — competitive landscape report
- IV iron dextran updates RSS · CI watch RSS
- Amgen portfolio CI